These two products (which share the same active ingredient) could be on track to become among the most successful drugs of all time, according to some analysts. Lilly has expanded its Mounjaro/Zepbound franchise into other indications as well, including obstructive sleep apnea.
Perhaps the greatest threats to Mounjaro and Zepbound come from Lilly's own pipeline. In April 2026, the company won U.S. regulatory approval of Foundayo (orforglipron), an oral obesity drug. Lilly is also evaluating promising obesity therapy retatrutide in late-stage clinical studies.
Eli Lilly's lineup features other successful products, too. They include the cancer drug Verzenio, the diabetes drug Jardiance, and the autoimmune disease drug Taltz.
3. Johnson & Johnson
Johnson & Johnson (JNJ -0.54%) is a healthcare giant that derives the majority of its growth from its pharmaceutical business. J&J boasts a large product lineup that includes immunology drugs Stelara and Tremfya and cancer drugs Darzalex and Erleada.